Quarterly report pursuant to Section 13 or 15(d)

SHAREHOLDERS' EQUITY

v3.24.0.1
SHAREHOLDERS' EQUITY
6 Months Ended
Dec. 31, 2023
SHAREHOLDERS' EQUITY  
SHAREHOLDERS' EQUITY

NOTE 7 — SHAREHOLDERS’ EQUITY

Changes in Shareholders’ Equity for the Three Months Ended December 31, 2023 and 2022

The following table presents changes in shareholders’ equity for the three months ended December 31, 2023 and 2022:

Accumulated

Additional

Other

Total

Common Stock

Paid-in

Comprehensive

Accumulated

Shareholders'

    

Shares

    

Amount

    

Capital

    

Loss

    

Deficit

    

Equity

Three Months Ended December 31, 2023:

Balances, September 30, 2023

 

36,827

$

37

$

379,320

$

(284)

$

(275,509)

$

103,564

Share-based compensation

1,837

1,837

Exercise of pre-funded warrants

2,798

3

(3)

Net change in accumulated other comprehensive loss

236

236

Net loss

 

 

 

 

 

(13,909)

 

(13,909)

Balances, December 31, 2023

39,625

$

40

$

381,154

$

(48)

$

(289,418)

$

91,728

Three Months Ended December 31, 2022:

Balances, September 30, 2022

36,827

$

37

$

372,082

$

$

(219,029)

$

153,090

Share-based compensation

1,731

1,731

Net loss

(13,556)

(13,556)

Balances, December 31, 2022

 

36,827

$

37

$

373,813

$

$

(232,585)

$

141,265

Jefferies Open Market Sales Agreement

On November 14, 2023, the Company and Jefferies LLC (the “Agent) entered into an Open Market Sale AgreementSM (the “Sales Agreement”) that provides for an “at the market” offering for the sale of up to $50.0 million in shares of the Company’s common stock (the “Placement Shares”) through the Agent. The Agent is acting as sales agent and is required to use commercially reasonable efforts to sell all of the Placement Shares requested to be sold by the Company, consistent with the Agent’s normal trading and sales practices,

on mutually agreed terms between the Agent and the Company. The Sales Agreement will terminate when all of the Placement Shares have been sold, or earlier upon the election of either the Company or the Agent.

The Company has no obligation to sell any of the Placement Shares under the Sales Agreement. The Company intends to use the net proceeds, if any, from amounts sold under the Sales Agreement for general corporate purposes, including working capital. Under the terms of the Sales Agreement, the Company agreed to pay the Agent a commission equal to 3.0% of the gross sales price of the Placement Shares plus certain expenses incurred by the Agent in connection with the offering.

For the six months ended December 31, 2023, the Company sold no shares of its common stock pursuant to the Sales Agreement. Accordingly, the maximum amount remaining for sale under the Sales Agreement amounts to $50.0 million as of December 31, 2023.

2022 Class B PFW Exercise

As discussed in Note 8, in October 2023, a holder of Class B PFW’s provided notice of cashless exercise of their 2,800,000 Class B PFW’s, resulting in the issuance of 2,797,404 shares of common stock on October 6, 2023.

2022 Private Placement

In May 2022, the Company entered into securities purchase agreements (“SPAs”) with Handok, Inc. (“Handok”) and certain of its affiliates. Handok is an affiliate of a member of the Company’s Board of Directors. In July 2022, the Company entered into amended SPAs for a private placement of common stock (the “2022 Private Placement”). The 2022 Private Placement resulted in gross proceeds of $12.3 million in exchange for the issuance of approximately 3.2 million shares of common stock. The Company incurred approximately $0.8 million for underwriting commissions and other offering costs, resulting in net proceeds of $11.5 million.